A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients - Archive ouverte HAL Access content directly
Journal Articles Cancer Immunology, Immunotherapy Year : 2009

A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients

(1) , (1) , (1) , (1) , (2, 3) , (4, 1) , (1) , (1)
1
2
3
4

Abstract

Melanoma reactive CTL were obtained by stimulating PBL from a melanoma patient in remission since 1994 following adjuvant TIL immunotherapy, with the autologous melanoma cell line. They were cloned by limiting dilution. One CTL clone recognized melanoma cell lines expressing tyrosinase and the B*4002 molecule, either spontaneously or upon transfection. We demonstrated that this clone recognizes the tyrosinase-derived nonapeptide 316-324 (ADVEFCLSL) and the overlapping decapeptide 315-324 (SADVEFCLSL). We derived two distinct additional speciWc CTL clones from this same patient that were also reactive against B*4002 melanoma cell lines, suggesting a relative diversity of this speciWc repertoire in this patient. Stimulating PBMC derived from four additional B*4002 melanoma patients with the tyrosinase 316-324 nonapeptide induced the growth of speciWc cells for two of the patients, demonstrating the immunogenicity of this new epitope. Our data show that this nonapeptide is a new tool that could be used to generate melanoma-speciWc T cells for adoptive immunotherapy or serve as a peptide vaccine for HLA-B*4002 melanoma patients.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-02481995 , version 1 (17-02-2020)

Identifiers

Cite

Yann Godet, Annabelle Bonnin, Yannik Guilloux, Virginie Vignard, Dirk Schadendorf, et al.. A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients. Cancer Immunology, Immunotherapy, 2009, 58 (2), pp.271 - 280. ⟨10.1007/s00262-008-0551-0⟩. ⟨inserm-02481995⟩
13 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More